Third Quarter Earnings Call Scheduled for November 2, 2020 AUSTIN, Texas , Oct. 7, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced 3 rd quarter 2020 revenues of approximately $106 million , up approximately 35% over the 3 rd quarter of 2019.
High-throughput diagnostic test will include most up-to-date respiratory pathogen targets AUSTIN, Texas , Sept. 24, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received a $5,389,813 award from the Biomedical Advanced Research and Development Authority
Project will expand utility of xMAP SARS-CoV-2 Multi-Antigen IgG Assay to better indicate whether individuals are protected against future infection AUSTIN, Texas , Sept. 23, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received an award of $683,500 from the
AUSTIN, Texas , Sept. 15, 2020 /PRNewswire/ -- On September 10, 2020 , Luminex Corporation (Nasdaq:LMNX) (the "Company"), announced that its board of directors declared a cash dividend for the third quarter of 2020 of $0.09 per share of common stock payable on October 15, 2020 to stockholders of
Long-time Chairman to retire AUSTIN, Texas , Aug. 4, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced the retirement of its Chairman, G. Walter Loewenbaum , from its Board of Directors ("Board") effective August 3, 2020 . "On behalf of Luminex's shareholders and Board, I
Delivers Accelerated Organic Growth and Profitability AUSTIN, Texas , Aug. 4, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its second quarter ended June 30, 2020 . All amounts in this release are in conformity with U.S.
Syndromic testing will streamline respiratory infection diagnosis as COVID-19 pandemic collides with start of flu season AUSTIN, Texas , July 22, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has submitted an EUA request to the FDA for a new expanded version of its
AUSTIN, Texas , July 20, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the second quarter ended June 30, 2020 on Tuesday, August 4, 2020 . A press release announcing the results is scheduled for release after the close of trading on that
- xMAP SARS-CoV-2 Multi-Antigen IgG Assay is enabled by xMAP Technology, the gold standard for multiplexing serologic testing - Antibody test detects previous COVID-19 infection with high specificity and high sensitivity in clinical studies, delivering comprehensive, accurate results while
Second Quarter Earnings Call Scheduled for August 3, 2020 AUSTIN, Texas , July 8, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced 2 nd quarter 2020 revenues of between $109 and $110 million , up more than 30% over the 2 nd quarter of 2019.
